William C. Shakespeare

7.1k citations

59 papers · 3.2k indexed · h-index 29

Molecular Biology top 5%
Oncology top 5%
Organic Chemistry top 2%
Hematology top 1%
Pulmonary and Respiratory Medicine top 5%

Co-authors: Victor M. Rivera David C. Dalgarno Tomi K. Sawyer Yihan Wang Tim Clackson Chester A. Metcalf Ralph Hirschmann Richard P. Johnson
Topics: Chronic Myeloid Leukemia Treatments (17 papers)Protein Kinase Regulation and GTPase Signaling (12 papers)Chemical Synthesis and Analysis (9 papers)
Cited by: Hematology Genetics Oncology
Journals: Proceedings of the National Academy of Sciences Journal of the American Chemical Society Blood
Partner nations: United States Spain South Korea

In The Last Decade

William C. Shakespeare

59 papers receiving 3.1k citations

Peers

Countries citing papers authored by William C. Shakespeare

Since Specialization

Citations

This map shows the geographic impact of William C. Shakespeare's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William C. Shakespeare with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William C. Shakespeare more than expected).

Fields of papers citing papers by William C. Shakespeare

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William C. Shakespeare. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William C. Shakespeare. The network helps show where William C. Shakespeare may publish in the future.

Co-authorship network of co-authors of William C. Shakespeare

This figure shows the co-authorship network connecting the top 25 collaborators of William C. Shakespeare. A scholar is included among the top collaborators of William C. Shakespeare based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William C. Shakespeare. William C. Shakespeare is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Ponatinib (AP24534), a Multitargeted Pan-FGFR Inhibitor with Activity in Multiple FGFR-Amplified or Mutated Cancer Models 2012 ·Molecular Cancer Therapeutics ·Joseph M. Gozgit,Matthew J. Wong,Lauren Moran,Scott Wardwell,Qurish K. Mohemmad,Narayana I. Narasimhan,William C. Shakespeare,Frank Wang,Tim Clackson,Victor M. Rivera	273
2	Abstract LB-298: AP26113, a potent ALK inhibitor, overcomes mutations in EML4-ALK that confer resistance to PF-02341066 (PF1066) 2010 ·Cancer Research ·Sen Zhang,Frank Wang,Jeffrey Keats,Yaoyu Ning,Scott Wardwell,Lauren Moran,Qurish K. Mohemmad,Rana Anjum,Yihan Wang,Xiaotian Zhu,Juan J. Miret,David C. Dalgarno,Narayana I. Narasimhan,Tim Clackson,William C. Shakespeare,Victor M. Rivera	44
3	AP24163 Inhibits the Gatekeeper Mutant of BCR‐ABL and Suppresses In vitro Resistance 2009 ·Chemical Biology & Drug Design ·Mohammad Azam,John T. Powers,William S. Einhorn,Wei‐Sheng Huang,William C. Shakespeare,Xiaotian Zhu,David C. Dalgarno,Tim Clackson,Tomi K. Sawyer,George Q. Daley	18
4	Structural Analysis of DFG‐in and DFG‐out Dual Src‐Abl Inhibitors Sharing a Common Vinyl Purine Template 2009 ·Chemical Biology & Drug Design ·Tianjun Zhou,Lois Commodore,Wei‐Sheng Huang,Yihan Wang,Tomi K. Sawyer,William C. Shakespeare,Tim Clackson,Xiaotian Zhu,David C. Dalgarno	23
5	Antiangiogenic and Antitumor Effects of Src Inhibition in Ovarian Carcinoma 2006 ·Cancer Research ·Liz Y. Han,Charles N. Landen,José G. Treviño,Jyotsnabaran Halder,Yvonne G. Lin,Aparna A. Kamat,Tae‐Jin Kim,William M. Merritt,Robert L. Coleman,David M. Gershenson,William C. Shakespeare,Yihan Wang,(unknown),Chester A. Metcalf,David C. Dalgarno,Tomi K. Sawyer,Gary E. Gallick,Anil K. Sood	68
6	Targeted inhibition of Gatekeeper variant “T315I” of BCR-ABL by a purine based ATP-competitive inhibitor 2006 ·Cancer Research ·Mohammad Azam,William C. Shakespeare,Tomi K. Sawyer,George Q. Daley	1
7	Src activation of Stat3 is an independent requirement from NF-κB activation for constitutive IL-8 expression in human pancreatic adenocarcinoma cells 2006 ·Angiogenesis ·José G. Treviño,Michael J. Gray,Steffan T. Nawrocki,Justin M. Summy,Donald P. Lesslie,Douglas B. Evans,Tomi K. Sawyer,William C. Shakespeare,Stephanie S. Watowich,Paul J. Chiao,David J. McConkey,Gary E. Gallick	42
8	Future Anti‐Catabolic Therapeutic Targets in Bone Disease 2006 ·Annals of the New York Academy of Sciences ·Brendan F. Boyce,Lianping Xing,Zhenqiang Yao,William C. Shakespeare,Yihan Wang,Chester A. Metcalf,Raji Sundaramoorthi,David C. Dalgarno,John D. Iuliucci,Tomi K. Sawyer	18
9	Vascular endothelial growth factor receptor-1 mediates migration of human colorectal carcinoma cells by activation of Src family kinases 2006 ·British Journal of Cancer ·Donald P. Lesslie,Justin M. Summy,Nila U. Parikh,Fei Fan,(unknown),Tomi K. Sawyer,Chester A. Metcalf,William C. Shakespeare,Daniel J. Hicklin,Lee M. Ellis,Gary E. Gallick	101
10	Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance 2006 ·Proceedings of the National Academy of Sciences ·Mohammad Azam,Valentina Nardi,William C. Shakespeare,Chester A. Metcalf,Regine S. Bohacek,Yihan Wang,Raji Sundaramoorthi,Piotr Sliz,Darren R. Veach,William G. Bornmann,Bayard Clarkson,David C. Dalgarno,Tomi K. Sawyer,George Q. Daley	87
11	Structural Basis of Src Tyrosine Kinase Inhibition with a New Class of Potent and Selective Trisubstituted Purine‐based Compounds 2005 ·Chemical Biology & Drug Design ·David C. Dalgarno,Thilo Stehle,Surinder S. Narula,P. Schelling,Marie Rose van Schravendijk,Susan Adams,Lawrence Andrade,Jeff Keats,Mary K. Ram,Lei Jin,Trudy H. Grossman,Ian A. MacNeil,Chester A. Metcalf,William C. Shakespeare,Yihan Wang,(unknown),Raji Sundaramoorthi,Regine S. Bohacek,Manfred Weigele,Tomi K. Sawyer	65
12	Protein Phosphorylation and Signal Transduction Modulation: Chemistry Perspectives for Small-Molecule Drug Discovery 2005 ·Medicinal Chemistry ·Tomi K. Sawyer,William C. Shakespeare,(unknown),Raji Sundaramoorthi,Wei Huang,(unknown),(unknown),B. Paige Lawrence,Leonard W. Rozamus,(unknown)	21
13	Bone-Targeted Src kinase inhibitors: novel pyrrolo- and pyrazolopyrimidine analogues 2003 ·Bioorganic & Medicinal Chemistry Letters ·Raji Sundaramoorthi,William C. Shakespeare,Terence P. Keenan,Chester A. Metcalf,Yihan Wang,(unknown),(unknown),Shuangying Liu,Regine S. Bohacek,Surinder S. Narula,David C. Dalgarno,(unknown),(unknown),Shuenn Liou,Susan Adams,Mary K. Ram,Jeffrey Keats,Manfred Weigele,Tomi K. Sawyer	14
14	Src Homology-2 Inhibitors: Peptidomimetic and Nonpeptide 2002 ·Mini-Reviews in Medicinal Chemistry ·Tomi K. Sawyer,Regine S. Bohacek,David C. Dalgarno,Charles J. Eyermann,(unknown),Chester A. Metcalf,William C. Shakespeare,Raji Sundaramoorthi,Yihan Wang,Michael G. Yang	42
15	A novel phosphotyrosine mimetic 4′-carboxymethyloxy-3′-phosphonophenylalanine (cpp): exploitation in the design of nonpeptide inhibitors of pp60Src SH2 domain 2001 ·Bioorganic & Medicinal Chemistry Letters ·(unknown),Michael G. Yang,George P. Luke,William C. Shakespeare,Raji Sundaramoorthi,Yihan Wang,D. T. Johnson,(unknown),Shelia M. Violette,Wei Guan,Catherine Bartlett,Jeremy A. Smith,Marcos Hatada,Xiaode Lu,David C. Dalgarno,Charles J. Eyermann,Regine S. Bohacek,Tomi K. Sawyer	16
16	SH2 domain inhibition: a problem solved? 2001 ·Current Opinion in Chemical Biology ·William C. Shakespeare	74
17	A Src SH2 selective binding compound inhibits osteoclast-mediated resorption 2000 ·Chemistry & Biology ·Shelia M. Violette,William C. Shakespeare,Catherine Bartlett,Wei Guan,Jeremy A. Smith,Richard J. Rickles,Regine S. Bohacek,Dennis A. Holt,Roland Baron,Tomi K. Sawyer	47
18	An efficient synthesis of a 4′-phosphonodifluoromethyl-3′-formyl-phenylalanine containing Src SH2 ligand 1999 ·Bioorganic & Medicinal Chemistry Letters ·William C. Shakespeare,Regine S. Bohacek,Surinder S. Narula,Mihai Azimioara,(unknown),David C. Dalgarno,(unknown),Martyn C. Botfield,Dennis A. Holt	10
19	A novel mechanism-based mammalian cell assay for the identification of SH2-domain-specific protein-protein inhibitors 1998 ·Chemistry & Biology ·Richard J. Rickles,(unknown),Wei Guan,Mihai Azimioara,William C. Shakespeare,Shelia M. Violette,Mark J. Zoller	6
20	1,2,3-cyclohexatriene and cyclohexen-3-yne: two new highly strained C6H6 isomers 1990 ·Journal of the American Chemical Society ·William C. Shakespeare,Richard P. Johnson	80

About William C. Shakespeare

William C. Shakespeare is a scholar working on Hematology, Genetics and Oncology, having authored 59 papers that have together received 3.2k indexed citations. Recurring topics across this work include Chronic Myeloid Leukemia Treatments (17 papers), Protein Kinase Regulation and GTPase Signaling (12 papers) and Chemical Synthesis and Analysis (9 papers). The work is most often cited by research in Hematology (666 citations), Genetics (461 citations) and Oncology (933 citations). William C. Shakespeare has collaborated with scholars based in United States, Spain and South Korea. Frequent co-authors include Victor M. Rivera, David C. Dalgarno, Tomi K. Sawyer, Yihan Wang, Tim Clackson, Chester A. Metcalf, Ralph Hirschmann, Richard P. Johnson, Raji Sundaramoorthi and Scott Wardwell. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of the American Chemical Society and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact